Incyte (INCY) Non-Current Deferred Tax Liability (2013 - 2015)
Incyte's (INCY) quarterly Non-Current Deferred Tax Liability came in at $9.7 million in Q3 2015, up 1153.16% YoY from $775000.0 in Q3 2014, and up 25.72% on a QoQ basis from $7.7 million in Q2 2015.
Incyte (INCY) Non-Current Deferred Tax Liability (2013 - 2015) Analysis & Trends
Incyte (INCY) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $9.7 million in Q3 2015.
- Quarterly Non-Current Deferred Tax Liability rose 1153.16% year-over-year to $9.7 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $9.7 million (up 1153.16% YoY) and the FY2014 annual result came in at $19.6 million, up 2094.53% from the prior year.
- Non-Current Deferred Tax Liability climbed to $9.7 million in Q3 2015, from $7.7 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $19.6 million in Q4 2014 to a low of $775000.0 in Q3 2014.
- A 3-year average of $5.8 million and a median of $3.5 million in 2014 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2014 — Non-Current Deferred Tax Liability surged 2094.53% — and 2015, when it jumped 575.45%.
- Tracing INCY's Non-Current Deferred Tax Liability over 3 years: stood at $895000.0 in 2013, then surged by 2094.53% to $19.6 million in 2014, then sank by 50.55% to $9.7 million in 2015.
- The last three Non-Current Deferred Tax Liability figures came in at $9.7 million (Q3 2015), $7.7 million (Q2 2015), and $6.0 million (Q1 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 9.71 Mn |
| Sep 30, 2015 | 9.71 Mn |
| Jun 30, 2015 | 7.73 Mn |
| Jun 30, 2015 | 7.73 Mn |
| Mar 31, 2015 | 6.03 Mn |
| Mar 31, 2015 | 6.03 Mn |
| Dec 31, 2014 | 19.64 Mn |
| Dec 31, 2014 | 19.64 Mn |
| Sep 30, 2014 | 775,000.00 |
| Sep 30, 2014 | 775,000.00 |
| Jun 30, 2014 | 900,000.00 |
| Jun 30, 2014 | 900,000.00 |
| Mar 31, 2014 | 892,000.00 |
| Mar 31, 2014 | 892,000.00 |
| Dec 31, 2013 | 895,000.00 |
| Dec 31, 2013 | 895,000.00 |